Alector, Inc. (ALEC): Capital Expenditures
$41.0K
Year ended 2025-12-31
$160.0K
Trailing 12 months to 2026-06-30
-78.5%
3-year compound annual growth
-61.8%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $41.0K | -96.7% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $1.25M | -47.3% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $2.38M | -42.2% | 2025-02-26, From 2023-01-01 |
| 2022-12-31 | $4.12M | +26.8% | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $3.25M | -35.5% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $5.03M | -67.0% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $15.27M | +710.2% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $1.88M | +135.2% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $801.0K | n/a | 2020-03-24, From 2017-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Alector, Inc. (ALEC) | 2025-12-31 | $41.0K | -96.7% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $827.0K | +76.7% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $574.0K | -81.6% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $99.0K | n/a |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $410.0K | -79.7% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $133.0K | n/a |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $522.0K | -7.6% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $85.0K | -66.0% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $0 | -100.0% |
Compare ALEC, LENZ, MGX, PTHS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗